Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
Eli Lilly
LLY
|
$534M |
| 2 |
Amazon
AMZN
|
$432M |
| 3 |
Abbott
ABT
|
$420M |
| 4 |
Adobe
ADBE
|
$365M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$277M |
Top Sells
| 1 |
Sherwin-Williams
SHW
|
$472M |
| 2 |
Bank of America
BAC
|
$426M |
| 3 |
TE Connectivity
TEL
|
$399M |
| 4 |
Atlassian
TEAM
|
$364M |
| 5 |
Goldman Sachs
GS
|
$348M |
Sector Composition
| 1 | Technology | 32.59% |
| 2 | Healthcare | 19.51% |
| 3 | Consumer Discretionary | 9.8% |
| 4 | Industrials | 9.76% |
| 5 | Financials | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
176
Vanguard S&P 500 ETF
VOO
$728B
| $209M | 0.12% |
478,835
+102,109
| +27% | +$44.6M |
|
177
Qualcomm
QCOM
$172B
| $209M | 0.12% |
1,445,835
-780
| -0.1% | -$113K |
|
178
Casey's General Stores
CASY
$18.8B
| $208M | 0.12% |
757,219
-16,686
| -2% | -$4.58M |
|
179
Constellium
CSTM
$2.04B
| $207M | 0.12% |
10,353,296
+11,527
| +0.1% | +$230K |
|
180
Schwab US Large- Cap ETF
SCHX
$59.2B
| $206M | 0.12% |
10,966,686
+34,038
| +0.3% | +$640K |
|
181
Johnson & Johnson
JNJ
$430B
| $205M | 0.12% |
1,305,009
-28,263
| -2% | -$4.43M |
|
182
Neurocrine Biosciences
NBIX
$14.3B
| $204M | 0.12% |
1,551,367
-165,687
| -10% | -$21.8M |
|
183
Elevance Health
ELV
$70.6B
| $198M | 0.12% |
419,232
-23,186
| -5% | -$10.9M |
|
184
Dollar Tree
DLTR
$20.6B
| $195M | 0.12% |
1,369,783
+6,762
| +0.5% | +$961K |
|
185
Tyler Technologies
TYL
$24.2B
| $193M | 0.12% |
462,134
-5,617
| -1% | -$2.35M |
|
186
United Therapeutics
UTHR
$18.1B
| $191M | 0.11% |
870,119
-6,449
| -0.7% | -$1.42M |
|
187
Marathon Petroleum
MPC
$54.8B
| $189M | 0.11% |
1,276,866
-190,984
| -13% | -$28.3M |
|
188
TransUnion
TRU
$17.5B
| $186M | 0.11% |
2,707,894
-468,600
| -15% | -$32.2M |
|
189
Occidental Petroleum
OXY
$45.2B
| $184M | 0.11% |
3,081,403
-156,351
| -5% | -$9.34M |
|
190
Sotera Health
SHC
$4.44B
| $175M | 0.1% |
10,367,812
+1,627,408
| +19% | +$27.4M |
|
191
Regal Rexnord
RRX
$9.66B
| $169M | 0.1% |
1,141,554
-430,013
| -27% | -$63.7M |
|
192
Xylem
XYL
$34.2B
| $168M | 0.1% |
1,468,960
-2,506
| -0.2% | -$287K |
|
193
Apollo Global Management
APO
$75.3B
| $166M | 0.1% |
1,782,667
-261,412
| -13% | -$24.4M |
|
194
Las Vegas Sands
LVS
$36.9B
| $165M | 0.1% |
3,361,082
+3,176,258
| +1,719% | +$156M |
|
195
Aptiv
APTV
$17.5B
| $165M | 0.1% |
1,842,610
+279,372
| +18% | +$25.1M |
|
196
Salesforce
CRM
$239B
| $165M | 0.1% |
627,455
+14,370
| +2% | +$3.78M |
|
197
Cencora
COR
$56.7B
| $165M | 0.1% |
803,867
-25,175
| -3% | -$5.17M |
|
198
Amicus Therapeutics
FOLD
$2.46B
| $163M | 0.1% |
11,507,129
-3,426,892
| -23% | -$48.6M |
|
199
Sensient Technologies
SXT
$4.79B
| $163M | 0.1% |
2,468,163
-102,767
| -4% | -$6.78M |
|
200
Novo Nordisk
NVO
$245B
| $162M | 0.1% |
1,569,564
+263,279
| +20% | +$27.2M |
|